Back

The selective rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates monocrotaline-induced pulmonary hypertension

26 August 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 1 - Understanding the pulmonary circulation Chronic pulmonary hypertension ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Silvia Cantoni

R&D Chiesi Farmaceutici S.P.A., Parma (Italy)

13 More presentations in this session

Presentation thumbnail
Increased central venous pressure is provoked not by pulmonary-circulation defects but by mild cardiac-strains in patients after Fontan procedure.
Doctor Y. Hamamichi (Tokyo, JP)
Abstract
Presentation thumbnail
Different hemodynamic profiles to exercise in COPD and IPF candidates to lung transplantation: role of the pulmonary arterial stiffness
Professor E. Peris Domingo (Barcelona, ES)
Abstract Slides
Presentation thumbnail
High-density lipoprotein cholesterol level as a predictor of long-term vasoreactivity in patients with idiopathic pulmonary arterial hypertension
Doctor K. Jonas (Krakow, PL)
Abstract Slides
Presentation thumbnail
ACE gene subtypes and pulmonary hypertension among patients with chronic obstructive pulmonary disease
Associate Professor C. Martiniuc (Chisinau, MD)
Abstract Slides
Presentation thumbnail
Mitochondrial permeability transition pore blocker prevents right ventricular mitochondrial damage in monocrtaline-induced pulmonary hypertension
Doctor D. Lee (Goyang, KR)
Abstract

Access the full session

Session thumbnail
Poster session 1 - Understanding the pulmonary circulation

The Event

Event poster

ESC Congress 2017

26 August - 30 August 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources